دورية أكاديمية
أعرض في EDS

Bioinformatics design of a peptide vaccine containing sarcoma antigen NY-SAR-35 epitopes against breast cancer and evaluation of its immunological function in BALB/c mouse model.

التفاصيل البيبلوغرافية
العنوان: Bioinformatics design of a peptide vaccine containing sarcoma antigen NY-SAR-35 epitopes against breast cancer and evaluation of its immunological function in BALB/c mouse model.
المؤلفون: Samman N; Department of Biotechnology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran., Mohabatkar H; Department of Biotechnology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran., Behbahani M; Department of Biotechnology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran., Ganjlikhani Hakemi M; Department of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.; Regenerative and Restorative Medicine Research Center (REMER), Research Institute for Health Sciences and Technologies (SABITA), Istanbul Medipol University, Istanbul, Turkey.
المصدر: PloS one [PLoS One] 2024 Jun 26; Vol. 19 (6), pp. e0306117. Date of Electronic Publication: 2024 Jun 26 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
أسماء مطبوعة: Original Publication: San Francisco, CA : Public Library of Science
مواضيع طبية MeSH: Cancer Vaccines*/immunology , Cancer Vaccines*/administration & dosage , Mice, Inbred BALB C* , Antigens, Neoplasm*/immunology , Computational Biology* , Vaccines, Subunit*/immunology , Breast Neoplasms*/immunology, Animals ; Mice ; Female ; Humans ; Epitopes, T-Lymphocyte/immunology ; Interleukin-4/immunology ; Interferon-gamma/immunology ; Interferon-gamma/metabolism ; Immunoglobulin G/immunology ; Immunoglobulin G/blood ; Granzymes ; Disease Models, Animal ; Protein Subunit Vaccines
مستخلص: The development of a cancer vaccine has become an essential focus in the field of medical biotechnology and immunology. In our study, the NY-SAR-35 cancer/testis antigen was targeted to design a novel peptide vaccine using bioinformatics tools, and BALB/c mice were used to evaluate the vaccine's immunological function. This evaluation involved assessing peptide-specific IgG levels in the serum via ELISA and measuring the levels of IFN-γ, IL-4, and granzyme B in the supernatant of cultured splenocytes. The final vaccine construct consisted of two T lymphocyte epitopes linked by the AAY linker. This construct displayed high antigenicity, non-allergenicity, non-toxicity, stability, and ability to induce IFN-γ and IL-4. It showed stable dynamics with both human MHC-I and II molecules, as well as mouse MHC-II molecules, and revealed strong Van der Waals and electrostatic energies. Emulsifying our peptide vaccine in incomplete Freund's adjuvant resulted in a remarkable increase in the levels of IgG. The splenocytes of mice that received the combination of peptide and adjuvant displayed a noteworthy increase in IFN-γ, IL-4, and granzyme B secretion. Additionally, their lymphocytes exhibited higher proliferation rates compared to the control group. Our data demonstrated that our vaccine could stimulate a robust immune response, making it a promising candidate for cancer prevention. However, clinical trials are necessary to assess its efficacy in humans.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright: © 2024 Samman et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
References: J Adv Vet Anim Res. 2019 Mar 24;6(2):174-182. (PMID: 31453188)
Biochem Biophys Res Commun. 2017 Mar 4;484(2):298-303. (PMID: 28126340)
Mol Immunol. 2019 Aug;112:93-102. (PMID: 31079006)
Hum Vaccin Immunother. 2021 Jan 2;17(1):22-34. (PMID: 32497486)
J Occup Med Toxicol. 2014 Jul 24;9:28. (PMID: 25071862)
Biol Direct. 2013 Dec 05;8:30. (PMID: 24304645)
Curr Comput Aided Drug Des. 2024;20(3):274-290. (PMID: 37309762)
J Comput Chem. 2005 Dec;26(16):1701-18. (PMID: 16211538)
Int Immunopharmacol. 2019 Sep;74:105719. (PMID: 31272065)
Int J Mol Sci. 2016 Jun 06;17(6):. (PMID: 27275820)
Clin Dev Immunol. 2013;2013:263952. (PMID: 24489573)
Int Immunopharmacol. 2019 Nov;76:105872. (PMID: 31499268)
Immunogenetics. 2011 Jun;63(6):325-35. (PMID: 21305276)
Front Immunol. 2021 Feb 17;11:615240. (PMID: 33679703)
J Proteome Res. 2020 Jun 5;19(6):2304-2315. (PMID: 32308001)
PLoS One. 2019 Oct 2;14(10):e0219693. (PMID: 31577808)
Vaccines (Basel). 2023 Jan 25;11(2):. (PMID: 36851141)
Curr Drug Targets. 2011 Dec;12(13):1957-73. (PMID: 21158706)
J Oncol. 2022 Mar 15;2022:9749363. (PMID: 35342400)
Vaccines (Basel). 2015 Jun 17;3(2):467-89. (PMID: 26343198)
Proc Natl Acad Sci U S A. 2009 Aug 11;106(32):13493-8. (PMID: 19651608)
J Biomol Struct Dyn. 2023 Sep 15;:1-18. (PMID: 37713338)
Nucleic Acids Res. 2020 Jul 2;48(W1):W449-W454. (PMID: 32406916)
Nucleic Acids Res. 2016 Jul 8;44(W1):W449-54. (PMID: 27131374)
BMC Bioinformatics. 2007 Jan 05;8:4. (PMID: 17207271)
Breast Cancer Res Treat. 2013 May;139(1):193-8. (PMID: 23580068)
Experientia. 1989 Jun 15;45(6):521-6. (PMID: 2500358)
Semin Cancer Biol. 2021 Nov;76:218-231. (PMID: 33910064)
Oncotarget. 2015 Jun 30;6(18):15772-87. (PMID: 26158218)
J Biomed Inform. 2019 May;93:103160. (PMID: 30928513)
Mol Biotechnol. 2023 Nov 7;:. (PMID: 37934390)
Nucleic Acids Res. 2007 Jul;35(Web Server issue):W407-10. (PMID: 17517781)
PLoS One. 2013 Sep 13;8(9):e73957. (PMID: 24058508)
Trends Cancer. 2018 Oct;4(10):701-712. (PMID: 30292353)
Exp Dermatol. 2002 Apr;11(2):126-34. (PMID: 11994139)
Adv Drug Deliv Rev. 2006 Oct 1;58(8):916-30. (PMID: 16979788)
Comput Appl Biosci. 1995 Dec;11(6):681-4. (PMID: 8808585)
Breast. 2022 Dec;66:15-23. (PMID: 36084384)
JAMA. 2019 Jan 22;321(3):288-300. (PMID: 30667505)
Drug Discov Today. 2020 Jun;25(6):1034-1042. (PMID: 32205198)
Bioinformatics. 2014 Mar 15;30(6):846-51. (PMID: 24167156)
Sci Rep. 2021 Nov 30;11(1):23121. (PMID: 34848739)
Cancer Cell Int. 2013 Sep 11;13(1):92. (PMID: 24025698)
J Hematol Oncol. 2022 Mar 18;15(1):28. (PMID: 35303904)
Front Immunol. 2021 Jun 30;12:696791. (PMID: 34276688)
Chem Soc Rev. 2023 May 9;52(9):2886-2910. (PMID: 37014050)
J Chem Inf Model. 2014 Jul 28;54(7):1951-62. (PMID: 24850022)
J Mol Model. 2014 Jun;20(6):2278. (PMID: 24878803)
Am J Obstet Gynecol. 2015 Aug;213(2):161-5. (PMID: 25747548)
Front Immunol. 2018 May 04;9:847. (PMID: 29780381)
Protein Sci. 1993 Sep;2(9):1511-9. (PMID: 8401235)
Ann Oncol. 2006 May;17(5):750-62. (PMID: 16293674)
J Biomol Struct Dyn. 2022 Sep;40(14):6363-6380. (PMID: 33599191)
Proc Natl Acad Sci U S A. 2013 May 28;110(22):E2046-53. (PMID: 23580623)
Nucleic Acids Res. 2018 Jul 2;46(W1):W443-W450. (PMID: 29746661)
PLoS One. 2010 Apr 16;5(4):e9862. (PMID: 20419125)
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2651-6. (PMID: 12601173)
Bioinformatics. 2017 Oct 01;33(19):3098-3100. (PMID: 28575391)
BMC Bioinformatics. 2008 Dec 02;9:514. (PMID: 19055730)
المشرفين على المادة: 0 (Cancer Vaccines)
0 (Antigens, Neoplasm)
0 (Vaccines, Subunit)
0 (Epitopes, T-Lymphocyte)
207137-56-2 (Interleukin-4)
82115-62-6 (Interferon-gamma)
0 (Immunoglobulin G)
EC 3.4.21.- (Granzymes)
0 (Protein Subunit Vaccines)
تواريخ الأحداث: Date Created: 20240626 Date Completed: 20240626 Latest Revision: 20240628
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC11207152
DOI: 10.1371/journal.pone.0306117
PMID: 38923980
قاعدة البيانات: MEDLINE
الوصف
تدمد:1932-6203
DOI:10.1371/journal.pone.0306117